Brazil widens market for drug-of-abuse IVDs with new legislation
This article was originally published in Clinica
Brazil’s lower house has passed draft legislation that promises to introduce widespread roadside testing of drivers for alcohol and drugs. Bill 5607/09, which will now go to the Senate for approval, has strong support from the health ministry, given the scale of the problem in terms of A&E and hospitalisation costs. In 2011, 155,000 hospitalisations were caused by traffic accidents – in which alcohol or drugs are thought to play a significant part. The cost to A&E services alone was R$200m (US$108m), claims the health ministry.
You may also be interested in...
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.